Type Public KK Headquarters Japan Founded 14 May 1897 Subsidiaries Sunovion | Traded as TYO: 4506 Founder Nagayo Sensai CEO Masayo Tada (2008–) Parent organization Sumitomo Chemical | |
Industry Biotech & Pharmaceuticals Predecessor Dainippon Pharmaceutical
Sumitomo Pharmaceuticals Key people Masayo Tada, (President and CEO) Products Diagnostics
Food additives
Food ingredients
Pharmaceuticals
Veterinary medicines Stock price 4506 (TYO) JP¥ 1,862 -47.00 (-2.46%)31 Mar, 1:00 PM GMT+9 - Disclaimer | ||
Sumitomo Dainippon Pharma Co., Ltd. (大日本住友製薬株式会社, Dainippon Sumitomo Seiyaku Kabushiki-Gaisha) is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.
The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly private company invested by a number of people in Tokyo and Osaka, with the land and buildings let by the government. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi, who were also among the first students trained abroad at government expense.
The company started its operation in 1885 with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to make a loss. in 1898 it was acquired by Osaka Seiyaku (Osaka Pharmaceutical).
Another origin of the company is Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical (holding 77.83% of the share as of 2006). Dainippon and Sumitomo merged on October 1, 2005 to create Dainippon Sumitomo Pharma. As a result, Sumitomo Chemical has 50.20% ownership in Dainippon Sumitomo Pharma as of March 31, 2014.
Sunovion
Sunovion (formerly Sepracor Inc.), was acquired by Sumitomo Dainippon in 2010, is a subsidiary now based in Marlborough, Massachusetts, USA.
In September 2016, the Sunovion announced it would acquire Cynapsus Therapeutics for approximately $624 million, specifically expanding Sunovians central nervous system drug portfolio. Through the deal, Sunovion would acquire Cynapsus’ Phase III Parkinson’s disease candidate drug APL-130277, a sublingual formulation of Apomorphine.